Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates

Rhea J. Longley(Walter and Eliza Hall Institute of Medical Research), Adrian V. S. Hill(Jenner Institute), Shahid M. Khan(Leiden University Medical Center), Alexandra J. Spencer(University of Oxford), Chris J. Janse(Leiden University Medical Center), Ahmed M. Salman(University of Oxford), Matthew G. Cottingham(University of Oxford), Katie Ewer(University of Oxford)
Scientific Reports
July 3, 2015
10.1038/srep11820
Cited by 57

Related Papers

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
|The Lancet|2020|5k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
|The Lancet|2021|1.2k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528